Two Week Sub-chronic Double-blinded Placebo Controlled Trial Designed to Determine if Sodium Pyruvate Nasal Spray Will Reduce the Symptoms, Duration and Replication of COVID-19 and Influenza Infections
Latest Information Update: 04 Nov 2022
At a glance
- Drugs Sodium pyruvate (Primary)
- Indications COVID 2019 infections; Influenza virus infections
- Focus Therapeutic Use
- Sponsors Cellular Sciences
- 25 Aug 2022 Status changed from recruiting to completed.
- 08 Apr 2021 New trial record
- 05 Apr 2021 Planned initiation date changed from 1 Mar 2021 to 3 Apr 2021.